Abstract | BACKGROUND: OBJECTIVE: Assess safety and efficacy of sargramostim in cancer and other diverse experimental and clinical settings. METHODS AND RESULTS: CONCLUSIONS:
|
Authors | Hillard M Lazarus, Carolyn E Ragsdale, Robert Peter Gale, Gary H Lyman |
Journal | Frontiers in immunology
(Front Immunol)
2021
Vol. 12
Pg. 706186
ISSN: 1664-3224 [Electronic] Switzerland |
PMID | 34484202
(Publication Type: Systematic Review)
|
Copyright | Copyright © 2021 Lazarus, Ragsdale, Gale and Lyman. |
Chemical References |
- Immunologic Factors
- Recombinant Proteins
- sargramostim
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- COVID-19
(immunology)
- Granulocyte-Macrophage Colony-Stimulating Factor
(immunology, therapeutic use)
- Humans
- Immunologic Factors
(therapeutic use)
- Immunotherapy
- Neoplasms
(drug therapy)
- Recombinant Proteins
(immunology, therapeutic use)
- SARS-CoV-2
(drug effects)
- COVID-19 Drug Treatment
|